Pivalate

Pivalate

SCHEMBL1831791

CC(C)(C)C(=O)O.c1ccncc1

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
NAPRT Q6XQN6 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
ALDH1A1 P00352 2/20 0.38
SLC22A12 Q96S37 3/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 2/20 0.35
APP P05067 1/20 0.34
GAA P10253 1/20 0.34
HCAR3 P49019 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
POLB P06746 1/20 0.33
TBXAS1 P24557 2/20 0.33
MAPK1 P28482 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pivalate SCHEMBL28353815 0.97 TSHR (0.47) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pyridine SCHEMBL19534751 0.86 ALDH1A1 (0.58) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pivalate SCHEMBL28268241 0.86 LMNA (0.39) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pivalamide SCHEMBL16446480 0.84 TDP1 (0.45) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pyridine SCHEMBL3722502 0.84 TDP1 (0.45) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pyridine SCHEMBL19534765 0.84 ALDH1A1 (0.55) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pivalate SCHEMBL27686624 0.82 TSHR (0.53) TSHRALDH1A1KMT2AMEN1CYP1A2
Pivalate SCHEMBL27675738 0.81 ALDH1A1 (0.36) TSHRNAPRTALDH1A1SLC22A12KMT2A
Pyridine SCHEMBL11731278 0.80 TSHR (0.41) TSHRNAPRTTDP1ALDH1A1SLC22A12
Pyridine SCHEMBL11104571 0.79 TSHR (0.60) TSHRNAPRTTDP1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1861364-B1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION C P PHARMACEUTICALS INTERNAT C V (US) 2011-05-11 EP claimed
JP-2008533128-A 2008-08-21 JP claimed
EP-1861364-A1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION Pfizer Science and Technology Ireland Limited (IE) 2007-12-05 EP claimed
WO-2006097909-A1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) 2006-09-21 WO claimed
CN-120519125-A Preparation method and application of polishing abrasive with cerium cluster coated substrate material 内蒙古大学 2025-08-22 CN disclosed
CN-112209917-B Application of heterocyclic substituted phenylpiperazine or phenylpiperidine derivatives in antidepressant drugs 上海医药工业研究院 2021-09-24 CN disclosed
CN-112209917-A Application of heterocyclic substituted phenyl piperazine (pyridine) derivatives in antidepressant drugs 上海医药工业研究院 2021-01-12 CN disclosed
CN-109843892-A Dislike diazepine ketone derivatives and its purposes in treatment hepatitis B infection 诺维拉治疗公司 2019-06-04 CN disclosed
CN-107580595-A Heterocyclic compounds and their use in the prevention or treatment of bacterial infections 拜欧蒂姆公司 2018-01-12 CN disclosed
CN-106573907-A Novel quinoline derivatives and their use in neurodegenerative diseases 默克专利有限公司 2017-04-19 CN disclosed
CN-104663674-A Fungicidal Mixtures DU PONT 2015-06-03 CN disclosed
CN-101969781-B Fungicidal compounds and mixtures DU PONT 2015-01-28 CN disclosed
EP-1861364-B1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION C P PHARMACEUTICALS INTERNAT C V (US) 2011-05-11 EP disclosed
EP-1861364-A1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION Pfizer Science and Technology Ireland Limited (IE) 2007-12-05 EP disclosed
WO-2006097909-A1 PREPARATION OF AN ATORVASTATIN INTERMEDIATE USING A PAAL-KNORR CONDENSATION PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) 2006-09-21 WO disclosed